Pmv Pharmaceuticals Stock Performance
| PMVP Stock | USD 1.43 0.02 1.42% |
The company holds a Beta of 0.59, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pmv Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Pmv Pharmaceuticals is expected to be smaller as well. At this point, Pmv Pharmaceuticals has a negative expected return of -0.18%. Please make sure to check Pmv Pharmaceuticals' value at risk and rate of daily change , to decide if Pmv Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pmv Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest unfluctuating performance, the Stock's basic indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
| Begin Period Cash Flow | 109.1 M | |
| Free Cash Flow | -56.6 M |
Pmv |
Pmv Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 163.00 in Pmv Pharmaceuticals on November 1, 2024 and sell it today you would lose (19.00) from holding Pmv Pharmaceuticals or give up 11.66% of portfolio value over 90 days. Pmv Pharmaceuticals is currently does not generate positive expected returns and assumes 2.4816% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Pmv, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pmv Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pmv Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pmv Pharmaceuticals, and traders can use it to determine the average amount a Pmv Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.071
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PMVP |
Estimated Market Risk
| 2.48 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pmv Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pmv Pharmaceuticals by adding Pmv Pharmaceuticals to a well-diversified portfolio.
Pmv Pharmaceuticals Fundamentals Growth
Pmv Stock prices reflect investors' perceptions of the future prospects and financial health of Pmv Pharmaceuticals, and Pmv Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pmv Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | (96.61 M) | ||||
| Shares Outstanding | 51.75 M | ||||
| Price To Book | 0.37 X | ||||
| EBITDA | (78.88 M) | ||||
| Cash And Equivalents | 277.43 M | ||||
| Cash Per Share | 6.08 X | ||||
| Total Debt | 13.29 M | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 3.82 X | ||||
| Cash Flow From Operations | (55.66 M) | ||||
| Earnings Per Share | (1.00) X | ||||
| Total Asset | 252.15 M | ||||
| Retained Earnings | (310 M) | ||||
About Pmv Pharmaceuticals Performance
Assessing Pmv Pharmaceuticals' fundamental ratios provides investors with valuable insights into Pmv Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Pmv Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey. Pmv Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 54 people.Things to note about Pmv Pharmaceuticals performance evaluation
Checking the ongoing alerts about Pmv Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pmv Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pmv Pharmaceuticals generated a negative expected return over the last 90 days | |
| Pmv Pharmaceuticals may become a speculative penny stock | |
| Pmv Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (68.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pmv Pharmaceuticals currently holds about 277.43 M in cash with (55.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pmv Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors |
- Analyzing Pmv Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pmv Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Pmv Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pmv Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pmv Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pmv Pharmaceuticals' stock. These opinions can provide insight into Pmv Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pmv Stock Analysis
When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.